直接抗病毒药物治疗儿童丙型肝炎1例报告

宁会彬; 刘俊平; 靳慧鸣; 李宽; 肖二辉; 尚佳

doi:10.3969/j.issn.1001-5256.2019.01.032

直接抗病毒药物治疗儿童丙型肝炎1例报告

DOI: 10.3969/j.issn.1001-5256.2019.01.032

河南省人民医院感染科

详细信息

中图分类号: R725.1
计量
- 文章访问数: 1332
- HTML全文浏览量: 15
- PDF下载量: 342
- 被引次数: 0
出版历程
- 出版日期: 2019-01-20

Direct-acting antiviral durgs for hepatitis C in children: A case report

Departmetn of Infectious Diseases, Henan Provincial People′s Hospital, Zhengzhou 450003, China

摘要

摘要:
<正>1病例资料患儿男性,5岁,主诉"体检发现丙型肝炎抗体阳性2年"于2017年8月23日入本院。患儿2年前体检发现抗-HCV阳性,当时无纳差、乏力、腹胀、恶心等不适,未治疗,定期每6个月于本院门诊复查。2017年8月10日于本院门诊随诊检查肝功能:ALT 37 U/L,AST 47 U/L,HCV RNA:2 954 969 IU/ml(采用实时荧光定量PCR,Abbott m2000全自动核酸检测仪,雅培原
- 肝炎,丙型 /
- 抗病毒药 /
- 儿童 /
- 病例报告
- hepatitis C /
- antiviral agents /
- child /
- case reports

HTML全文

参考文献(12)

[1]WHO.Global hepatitis report 2017[EB/OL]. (2017-08-20) .http://www.who.int/hepatitis/publications/globalhepatitisreport 2017/en/.

[2]GOWER E, ESTES C, BLACH S, et al.Global epidemiology and genotype distribution of the hepatitis C virus infection[J].J Hepatol, 2014, 61 (1) :45-57.

[3]INDOLFI G, HIERRO L, DEZSOFI A, et al.Treatment of chronic hepatitis C virus infection in children.A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition[J].J Pediatr Gastroenterol Nutr, 2018, 66 (3) :505-515.

[4]INDOLFI G, THORNE C, SAYED MH, et al.The challenge of treating children with hepatitis C virus infection[J].J Pediatr Gastroentero Nutr, 2017, 64 (6) :851-854.

[5]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment of hepatitis C:A 2015 update[J].JClin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[6]CHENG DY, LIU XM, OU WN, et al.Clinical efficacy of directacting antiviral agents in patients with HCV-related liver cirrhosis[J].Chin J Exp Clin Infect Dis:Electronic Edition, 2017, 11 (6) :545-549. (in Chinese) 程丹颖, 刘晓民, 欧蔚妮, 等.直接抗病毒药物治疗丙型肝炎肝硬化患者的疗效观察[J].中华实验和临床感染病杂志:电子版, 2017, 11 (6) :545-549.

[7]BALISTRERI WF, MURRAY KF, ROSENTHAL P, et al.The safety and effectiveness of ledipasvir sofosbuvir in adolescents 12-17years old with hepatitis C virus genotype 1 infection[J].Hepatology, 2017, 66 (2) :371-378.

[8]WIRTH S, ROSENTHAL P, GONZALEZ-PERALTA RP, et al.Sofosbuvir and ribavirin in adolescents 12 to 17 years old with hepatitis C virus genotype 2 or 3 infection[J].Hepatology, 2017, 66 (4) :1102-1110.

[9]The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Present.HCV guidance:recommendations for testing, managing, and treating hepatitis C[S/OL]. (2017-09-21) .http://www.Hcvguidelines.org.

[10]NAN YM, LI DD, KONG LB.Focus on the treatment of chronic hepatitis C in children[J].J Clin Hepatol, 2018, 34 (2) :246-250. (in Chinese) 南月敏, 李冬冬, 孔令波.关注儿童慢性丙型肝炎的治疗[J].临床肝胆病杂志, 2018, 34 (2) :246-250.

[11]MURRAY KF, BALISTRERI W, BANSAL S, et al.Ledipasvir/sofosbuvir±ribavirin for 12 or 24 weeks is safe and effective in children 6-11 years old with chronic hepatitis C infection[J].J Hepatol, 2017, 66 (1) :57-58.

[12]XIE L, HAO P, WU RH, et al.Establishment and application of a database for hepatitis C virus NS3/4A protease inhibitors and their drug resistance data[J].J Clin Hepatol, 2018, 34 (8) :1884-1890. (in Chinese) 谢磊, 郝沛, 吴瑞红, 等.HCV NS3/4A蛋白酶抑制剂药物及其耐药信息数据库的建立和应用[J].临床肝胆病杂志, 2018, 34 (8) :1884-1890.

施引文献

资源附件(0)

访问统计